Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dacarbazine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    95 result(s) found for: Dacarbazine. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2013-003545-41 Sponsor Protocol Number: D1344C00001 Start Date*: 2014-04-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic...
    Medical condition: Metastatic uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025654 Malignant melanoma of sites other than skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DE (Completed) NL (Completed) FI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005737-11 Sponsor Protocol Number: PH-L19IL2 DTIC - 03/07 Start Date*: 2008-01-17
    Sponsor Name:PHILOGEN S.P.A.
    Full Title: Dose definition and activity evaluation study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine in patients with metastatic melanoma
    Medical condition: unresectable metastatic (stage IV)non-uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025654 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-006082-14 Sponsor Protocol Number: CA184024 Start Date*: 2006-08-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multi-Center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients with Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg of Ipilimumab (MDX-010) vs....
    Medical condition: Stage III (Unresectable) or IV Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) IE (Completed) BE (Completed) HU (Completed) ES (Completed) PT (Completed) DE (Completed) GB (Completed) CZ (Completed) AT (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003718-16 Sponsor Protocol Number: CA209-066 Start Date*: 2013-04-04
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects with Previously Untreated Unresectable or Metastatic Melanoma Country specific Protocol Amendment 05, dated 09-...
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) ES (Completed) DK (Completed) NO (Completed) IT (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000725-30 Sponsor Protocol Number: BAY 43-9006/11538 Start Date*: 2007-11-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: A phase II, multi-centre, open-label, uncontrolled study to evaluate the efficacy and safety of BAY 43-9006 given daily in combination with repeated 21-day cycles of dacarbazine (DTIC) chemotherapy...
    Medical condition: Subjects with advanced, metastatic, histologically confirmed melanoma, for whom treatment with dacarbazine is considered medically acceptable. Subjects should have measurable and evaluable disease ...
    Disease: Version SOC Term Classification Code Term Level
    10027481
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002130-18 Sponsor Protocol Number: C1034T02 Start Date*: 2007-02-19
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 1/2 , Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human av Integrins (CNTO 95), Alone and in Combination with Dacarbaz...
    Medical condition: Malignant Melanoma Stage IV
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007265-20 Sponsor Protocol Number: IPH1101-205 Start Date*: 2008-03-06
    Sponsor Name:Innate Pharma
    Full Title: A Phase II open label randomized parallel group non comparative trial to assess efficacy and safety of the association of IPH1101 and IL-2 alone and in combination with dacarbazine, in patients wit...
    Medical condition: metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005538-20 Sponsor Protocol Number: BA2011/15/02 Start Date*: 2012-05-15
    Sponsor Name:BioAlliance Pharma
    Full Title: SAFETY AND EFFICACY OF INTRAMUSCULAR ELECTROTRANSFER OF PLASMID AMEP IN PATIENTS SUFFERING FROM ADVANCED OR METASTATIC MELANOMA: AN OPEN-LABEL PHASE I/II CLINICAL TRIAL THE AIMM STUDY (AMEP IN MET...
    Medical condition: Treatment of patients suffering from advanced or metastatic melanoma (stages III, IV)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001161-34 Sponsor Protocol Number: APL-B-016-05 Start Date*: 2005-10-03
    Sponsor Name:Pharma Mar SA
    Full Title: Phase I-II multicenter, randomized, open-label, clinical and pharmacokinetic study of plitidepsin, administered alone or in combination with dacarbazine, as front-line therapy to subjects with unre...
    Medical condition: unresectable advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    5.0 10027150 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012293-12 Sponsor Protocol Number: NO25026 Start Date*: 2010-01-25
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: BRIM 3: A Randomized, Open-label, Controlled, Multicenter, Phase III Study in Previously untreated Patients with Unresectable Stage IIIC or Stage IV Melanoma with V600E BRAF mutation Receiving Vemu...
    Medical condition: First-line therapy for adult patients with histologically confirmed metastatic melanoma (unresectable Stage IIIC or Stage IV) harbouring the V600E positive mutation
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) SE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006713-16 Sponsor Protocol Number: CP12-0604 Start Date*: 2008-09-02
    Sponsor Name:ImClone Systems Incorporated
    Full Title: Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients with Metastatic Malignant Melanoma
    Medical condition: Metastatic Malignant Melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001828-35 Sponsor Protocol Number: CA209-037 Start Date*: 2013-02-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Open-Label Phase III Trial of BMS-936558 versus Investigator’s Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy Pharmacogenetic...
    Medical condition: Unresectable or metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006344-19 Sponsor Protocol Number: D1532C00006 Start Date*: 2009-09-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Double-Blind, Randomised Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Dacarbazine Compared with Dacarbazine Alone in First Line Patients with BRAF Mutation ...
    Medical condition: BRAF mutation positive advanced cutaneous and unknown primary melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025654 Malignant melanoma of sites other than skin LLT
    9.1 10025670 Malignant melanoma stage III LLT
    9.1 10025671 Malignant melanoma stage IV LLT
    9.1 10027152 Melanoma of skin (malignant) LLT
    9.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) CZ (Completed) FR (Completed) SE (Completed) HU (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002669-37 Sponsor Protocol Number: EMR200066-007 Start Date*: 2013-02-20
    Sponsor Name:Merck Serono S.A. Geneva
    Full Title: A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cuta...
    Medical condition: N-RAS mutated locally advanced or metastatic malignant cutaneous melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10025655 Malignant melanoma of skin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) DE (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004027-17 Sponsor Protocol Number: SGN35-027 Start Date*: 2021-09-23
    Sponsor Name:Seagen Inc.
    Full Title: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
    Medical condition: Classical Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003593-51 Sponsor Protocol Number: CMEK162A2301 Start Date*: 2013-03-27
    Sponsor Name:Array BioPharma Inc.
    Full Title: The NEMO trial (NRAS melanoma and MEK inhibitor): A randomized Phase III, open label, multicenter, two-arm study comparing MEK162 versus dacarbazine in patients with advanced unresectable or metast...
    Medical condition: metastatic or unresectable cutaneous melanoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) AT (Completed) CZ (Completed) DE (Completed) ES (Completed) GB (Completed) NL (Completed) BE (Completed) IT (Completed) HU (Completed) GR (Completed) SE (Completed) PL (Completed) PT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-004097-32 Sponsor Protocol Number: CA033 Start Date*: 2009-07-30
    Sponsor Name:Abraxis BioScience, LLC, a wholly owned subsidiary of Celgene Corporation
    Full Title: An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients with Metastatic Malignant Melanoma
    Medical condition: Metastatic Malignant Melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-008794-55 Sponsor Protocol Number: RDD299 Start Date*: 2010-05-17
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust
    Full Title: A randomised phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma
    Medical condition: Metastatic Uveal Melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025654 Malignant melanoma of sites other than skin PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024483-17 Sponsor Protocol Number: E7389-G000-309 Start Date*: 2011-06-30
    Sponsor Name:Eisai Ltd
    Full Title: A Randomised, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Dacarbazine in Subjects with Soft Tissue Sarcoma.
    Medical condition: Soft tissue sarcoma (STS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) GB (Completed) AT (Completed) DK (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004103-40 Sponsor Protocol Number: ALDOXORUBICIN-P3-STS-01 Start Date*: 2014-03-20
    Sponsor Name:CytRx Corporation
    Full Title: A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator’s Choice in Subjects with Metastatic, Locally Advanced, or Unres...
    Medical condition: Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) DK (Prematurely Ended) BG (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Nov 01 23:15:04 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA